REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

Public trial

Effects of Yoga on the lives of caregivers of children with Autism in Acre

Date of registration: 11/17/2025 ^(mm/dd/yyyy)
Last approval date : 11/17/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Mindfulness program for federal public servants in southern Brazil: effects on anxiety, stress, mindfulness, and well-being

Date of registration: 11/17/2025 ^(mm/dd/yyyy)
Last approval date : 11/17/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Using Constraint-Induced Movement Therapy to Improve Walking and Movement in People with Neurological Diseases

Date of registration: 11/17/2025 ^(mm/dd/yyyy)
Last approval date : 11/17/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Exercises with Blood Flow Restriction and Electrical Stimulation for Diabetic Nerve Pain: Practical Study

Date of registration: 11/17/2025 ^(mm/dd/yyyy)
Last approval date : 11/17/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Using Virtual Reality to relieve pain and anxiety during Hemodialysis access puncture

Date of registration: 11/16/2025 ^(mm/dd/yyyy)
Last approval date : 11/16/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison between two regional anesthesia techniques to relieve pain after partial breast removal surgery (Quadrantectomy)

Date of registration: 11/16/2025 ^(mm/dd/yyyy)
Last approval date : 11/16/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of using a vibratory device to help babies with Bronchiolitis

Date of registration: 11/14/2025 ^(mm/dd/yyyy)
Last approval date : 11/14/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Number of sessions required to achieve maximum tooth whitening with 35% hydrogen peroxide

Date of registration: 11/14/2025 ^(mm/dd/yyyy)
Last approval date : 11/14/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study on the effects of alternating between sitting and standing during office work on adults’ health, comfort, and well-being

Date of registration: 11/14/2025 ^(mm/dd/yyyy)
Last approval date : 11/14/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study on the proposal for pre-rehabilitation work and health-related quality of life of adults with visual impairment who are on the waiting list

Date of registration: 11/14/2025 ^(mm/dd/yyyy)
Last approval date : 11/14/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Bacteria-produced dressing for treating wounds in diabetic patients

Date of registration: 11/14/2025 ^(mm/dd/yyyy)
Last approval date : 11/14/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of low-level laser Photobiomodulation on breast milk production in postpartum women: a randomized clinical trial

Date of registration: 11/13/2025 ^(mm/dd/yyyy)
Last approval date : 11/13/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Efficacy of different physical therapy delivery modalities on adherence and pain in individuals with chronic low back pain

Date of registration: 11/13/2025 ^(mm/dd/yyyy)
Last approval date : 11/13/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

How eating functional foods can help people living with HIV to improve their metabolism and nutrition

Date of registration: 11/13/2025 ^(mm/dd/yyyy)
Last approval date : 11/13/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Prevalence of major depressive disorder and treatment-resistant depression in the mental health reference service of Araraquara

Date of registration: 11/13/2025 ^(mm/dd/yyyy)
Last approval date : 11/13/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Parasternal block with local anesthetic in cardiac surgery via sternotomy

Date of registration: 11/13/2025 ^(mm/dd/yyyy)
Last approval date : 11/13/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Modified Breathing Exercise: effect on respiratory function

Date of registration: 11/13/2025 ^(mm/dd/yyyy)
Last approval date : 11/13/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Enavogliflozin PK/PD profile evaluation in healthy brazilian subjects

Date of registration: 11/12/2025 ^(mm/dd/yyyy)
Last approval date : 11/12/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical study for the treatment of Halitosis

Date of registration: 11/12/2025 ^(mm/dd/yyyy)
Last approval date : 11/12/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Multicomponent Exercise Combined with Strategies to Promote an Active Lifestyle in Older Adults with Cognitive Impairment (MOVEMENTE Study)

Date of registration: 11/12/2025 ^(mm/dd/yyyy)
Last approval date : 11/12/2025 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

…
17
18
19
20
21
22
23
24
25
…
447

Username/Password

News

02/26/2026

Brazilian Ministry of Health Includes High-Tech Test for Rare Diseases in SUS (Brazilian Public Health System). Families' Waiting Time for Diagnosis Reduced from 7 Years to Six Months

02/26/2026 | Ministry of Health

https://www.gov.br/saude/pt-br/assuntos/noticias/2026/fevereiro/ministerio-da-saude-inclui-exame-de-alta-tecnologia-no-sus-para-doencas-raras-espera-das-familias-por-diagnostico-reduz-de-7-anos-para-seis-meses

Complete Exome Sequencing will be available in the public network with the capacity to meet 100% of the demand. In the private network, the cost is up to R$ 5,000 per patient.

The Ministry of Health announced, this Thursday (26), the beginning of the offer in the SUS (Brazilian Public Health System) of an innovative, high-technology genetic test for the confirmation of the diagnosis of rare genetic diseases. This refers to Whole Exome Sequencing (WES), which will address 90% of cases in Brazil requiring timely test results. This is one of the main bottlenecks faced by families, who will receive results in up to six months (previously seven years). This represents a 93% reduction in waiting time.

During the week of World and National Rare Disease Day, celebrated on February 28th, the Ministry also announced an investment of R$ 26 million/year to expand the availability of the test throughout the country. In the private sector, Whole Exome Sequencing can cost up to R$ 5,000. In the public sector, it will be free. Currently, approximately 13 million Brazilians have one of the 7,000 cataloged rare diseases, with more than 70% of genetic origin.

“When the SUS (Brazilian Public Health System) starts offering complete genetic sequencing, an exam that can cost up to R$ 5,000, we are breaking a historical barrier to access. This will reduce the diagnosis time, which today can take up to seven years, to a few months, completely changing the quality of life…

02/26/2026

Fiocruz Initiates Clinical Studies with Innovative Gene Therapy for Spinal Muscular Atrophy

02/26/2026 | Fiocruz

https://agencia.fiocruz.br/fiocruz-inicia-estudos-clinicos-com-terapia-genica-inovadora-para-atrofia-muscular-espinhal

In partnership with the Ministry of Health (MS), Fiocruz has begun the first human clinical study of GB221, a gene therapy product that integrates the new generation of this class of products, aimed at treating Spinal Muscular Atrophy (SMA) Type 1 (SMA1), the most severe form of the disease. The clinical research represents an advance in the development of gene therapies, one of the most innovative frontiers of precision public health, focusing on the Unified Health System (SUS).

The project is being conducted by Fiocruz in partnership with Gemma Biotherapeutics, Inc. (GEMMABio), the technology holder and sponsor of the study within the scope of the National Health Surveillance Agency (Anvisa); Intrials Pesquisa Clínica Ltda; Casa dos Raros; and the Hospital de Clínicas de Porto Alegre (HCPA).

The announcement took place this Thursday (February 26th) in Brasília, during an event organized by the Ministry of Health commemorating World Rare Disease Day (February 28th). SMA is a rare disease that manifests in the first months of life and is caused by an alteration in the SMN1 gene, responsible for producing a protein essential for the functioning of neurons that control movement. The absence of this protein causes progressive loss of muscle strength and can compromise the survival of children in the first years of life.

New technological frontier in Brazil

The ongoing clinical study is part of the process of incorporating this technology within the context of the Fiocruz Strategy for Advanced Therapies. The goal is to provide the country with the scientific, technological, production, and healthcare infrastructure…

02/26/2026

In a groundbreaking clinical trial in the US, the first autistic person receives a dose of gene therapy

02/26/2026 | Francisco Paiva Jr. | Canal Autismo

https://www.canalautismo.com.br/noticia/em-estudo-clinico-inedito-nos-eua-primeiro-autista-recebe-dose-de-terapia-genetica/

An important milestone for science occurred this week: for the first time in the world, an autistic person received a dose of gene therapy. The announcement was made yesterday (February 25, 2026) in the United States by the pharmaceutical laboratory Mahzi Therapeutics, using technology developed by the Muotri Lab at the University of California, San Diego (UCSD). The dose is part of the clinical study called “UNITE,” a phase 1/2 clinical trial of the gene therapy MZ-1866, specifically designed for a type of syndromic autism, Pitt-Hopkins syndrome, which affects a single gene, TCF4, based on research using mini-brains (cerebral organoids). The patient is a level 3 autistic individual requiring support.

The study is led by Brazilian neuroscientist Dr. Alysson Muotri, a professor at the UCSD medical school, who celebrated: “The first individual on autism spectrum level 3 to be treated in a clinical trial is an important milestone for validating the gene therapy strategy (a substance that will act directly on the specific gene) for ASD. Even more relevant is that all of this was discovered using a human model, brain organoids, which are generated in the laboratory from the patients' own cells. With the clinical trial, we will evaluate the impact of this strategy on the brain, which symptoms can be reversed, and if there are any unexpected side effects in this type of approach. It is no longer a distant dream; it is becoming a reality,” said Muotri, who is also the co-founder of the startup Tismoo in Brazil, exclusively to Revista Autismo.

The Unite study (Phase 1/2) is a multicenter, open-label, global…

02/26/2026

New Treatment Helps Reduce Hot Flashes in Prostate Cancer Therapy

02/26/2026 | Sharon Theimer | Mayo Clinic

https://newsnetwork.mayoclinic.org/pt/2026/02/26/novo-tratamento-ajuda-a-reduzir-ondas-de-calor-em-terapia-para-cancer-de-prostata/

A drug widely used to treat overactive bladder significantly reduced hot flashes in men undergoing hormone therapy for prostate cancer, according to a study published in the Journal of Clinical Oncology involving several Mayo Clinic researchers.

The phase 2 study demonstrated that oxybutynin, a drug commonly prescribed to treat overactive bladder, was more effective than placebo in reducing the frequency and intensity of hot flashes in men undergoing hormone therapy for prostate cancer. Participants who received oxybutynin also reported improvements in daily activities and overall quality of life.

Hot flashes are estimated to affect between 60% and 80% of men undergoing androgen deprivation therapy, potentially interfering with sleep, mood, and overall well-being. In some cases, the symptoms are so intense that they hinder the continuation of treatment.

“Hot flashes are often underestimated in men, but they can have a real and lasting impact on quality of life during prostate cancer treatment,” says Bradley Stish, M.D., a radiation oncologist at the Mayo Clinic and first author of the study. “This clinical trial shows that oxybutynin can provide significant relief, with a favorable safety profile.”

The study included 88 men with prostate cancer who experienced frequent hot flashes while receiving androgen deprivation therapy. Participants were randomly assigned to receive oxybutynin at one of two doses or a placebo for six weeks.

Men who received the highest dose of oxybutynin experienced the greatest benefit, with an average reduction of nearly seven hot flash episodes per…

02/25/2026

Butantan to Advance Delivery of 1.3 Million Doses of Dengue Vaccine

02/23/2026 | Jessica Bernardo | Metrópolis

https://www.metropoles.com/sao-paulo/butantan-antecipara-entrega-de-13-milhao-de-doses-da-vacina-da-dengue

Vaccine, which was scheduled for delivery in the second half of the year, should arrive at the Ministry of Health by the end of June.

The Butantan Institute will advance the delivery of 1.3 million doses of the dengue vaccine, Butantan-DV, to the Ministry of Health. The shipment of immunizing agents was only scheduled for the second half of this year.

The information was announced this Monday (February 23rd) by Governor Tarcísio de Freitas (Republicanos) and the director of the Butantan Institute, Esper Kállas, at the ceremony marking the 125th anniversary of Butantan, at the institution's headquarters in the western part of São Paulo.

“We are going to bring forward 1.3 million doses that were planned for the second semester and will now deliver them in the first semester. Starting with 200,000 doses that will be delivered this February,” stated Tarcísio.

In total, the Ministry of Health contracted the production of 3.9 million doses of the vaccine with Butantan, for R$ 368 million. The first shipment, also of 1.3 million vaccines, was completed in January of this year. The last batch of contracted vaccines should arrive at the Ministry of Health in 2027.